Infant botulism

disease
On this page

Also known as botulism of infancyinfant intestinal botulisminfant intestinal toxaemia botulisminfant intestinal toxemia botulisminfant intestinal toxin-mediated botulisminfantile botulisminfantile onset botulism

Summary

Infant botulism (MONDO:0015804) is a disease and 1 clinical trial. A subtype of intestinal botulism — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: 1-9 / 1 000 000 (Europe) [Orphanet-validated]
  • Phenotypes (HPO): 28
  • Clinical trials: 1

Clinical features

Epidemiology

Prevalence records

4 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence1-9 / 1 000 0000.3EuropeValidated
Prevalence at birth1-9 / 1 000 0000.2EuropeValidated
Prevalence at birth1-9 / 100 0002.1United StatesValidated
Prevalence at birth1-9 / 100 0002.2ArgentinaValidated

Signs & symptoms

Clinical features (HPO)

28 HPO clinical features (Orphanet curated; top 28 by frequency):

HPO IDTermFrequency
HP:0000217XerostomiaVery frequent (80-99%)
HP:0000298Mask-like faciesVery frequent (80-99%)
HP:0000508PtosisVery frequent (80-99%)
HP:0000651DiplopiaVery frequent (80-99%)
HP:0001097Keratoconjunctivitis siccaVery frequent (80-99%)
HP:0001252HypotoniaVery frequent (80-99%)
HP:0001260DysarthriaVery frequent (80-99%)
HP:0001620Abnormally high-pitched voiceVery frequent (80-99%)
HP:0002015DysphagiaVery frequent (80-99%)
HP:0002019ConstipationVery frequent (80-99%)
HP:0002039AnorexiaVery frequent (80-99%)
HP:0002307DroolingVery frequent (80-99%)
HP:0002360Sleep abnormalityVery frequent (80-99%)
HP:0006824Cranial nerve paralysisVery frequent (80-99%)
HP:0011499MydriasisVery frequent (80-99%)
HP:0100021Cerebral palsyVery frequent (80-99%)
HP:0100022Abnormality of movementVery frequent (80-99%)
HP:0000600Abnormality of the pharynxFrequent (30-79%)
HP:0000822HypertensionFrequent (30-79%)
HP:0001284AreflexiaFrequent (30-79%)
HP:0002094DyspneaFrequent (30-79%)
HP:0002607Bowel incontinenceFrequent (30-79%)
HP:0002615HypotensionFrequent (30-79%)
HP:0002747Respiratory insufficiency due to muscle weaknessFrequent (30-79%)
HP:0000389Chronic otitis mediaOccasional (5-29%)
HP:0001695Cardiac arrestOccasional (5-29%)
HP:0002027Abdominal painOccasional (5-29%)
HP:0002902HyponatremiaOccasional (5-29%)

Identifiers

Disease identifiers

FieldValue
Canonical nameinfant botulism
Mondo IDMONDO:0015804
Orphanet178478
DOIDDOID:0050354
ICD-10-CMA48.51
NCITC128343
SNOMED CT414488002
UMLSC0238027
MedGen68649
GARD0020150
Is cancer (heuristic)no

Also known as: botulism of infancy · infant intestinal botulism · infant intestinal toxaemia botulism · infant intestinal toxemia botulism · infant intestinal toxin-mediated botulism · infantile botulism · infantile onset botulism

Disease family

This is a subtype of intestinal botulism. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious diseasebacterial infectious diseaseprimary bacterial infectious diseasebotulismtoxin-mediated infectious botulismintestinal botulisminfant botulism

Related subtypes (1): adult intestinal botulism

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00004401Not specifiedCOMPLETEDStudy of Human Botulism Immunoglobulin in Infants With Botulism

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.